Inna M. Yasinska

Inna M. Yasinska


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
IYInna M. Yasinska
Inna M. Yasinska
NMN. Helge Meyer
N. Helge Meyer
SSStephanie Schlichtner
Stephanie Schlichtner
RHRohanah Hussain
Rohanah Hussain
GSGiuliano Siligardi
Giuliano Siligardi
Vadim SumbayevVadim Sumbayev
Vadim Sumbayev
Acute myeloid leukemia (AML), a blood/bone marrow cancer, is a severe and often fatal malignancy. AML cells are capable of impairing the anti-cancer activities of cytotoxic lymphoid cells. This includes the inactivation of natural killer (NK) cells and killing of T lymphocytes. Here we report for the first time that V-domain Ig-containing suppressor of T cell activation (VISTA), a protein expressed by T cells, recognizes galectin-9 secreted by AML cells as a ligand. Importantly, we found that soluble VISTA released by AML cells enhances the effect of galectin-9, most likely by forming multiprotein complexes on the surface of T cells and possibly creating a molecular barrier. These events cause changes in the plasma membrane potential of T cells leading to activation of granzyme B inside cytotoxic T cells, resulting in apoptosis.